Augusto de Leon
Internal Medicine · Palm Coast, FLNPI 1982664165
Payments from drug & device makers
Across 194 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$502
- AbbVie$487
- Amgen$383
- GSK$311
- AstraZeneca$199
- Lilly USA, LLC$180
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,409100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $502 |
| AbbVie | 25 | $487 |
| Amgen | 20 | $383 |
| GSK | 22 | $311 |
| AstraZeneca | 11 | $199 |
| Lilly USA, LLC | 10 | $180 |
| Otsuka America Pharmaceutical, Inc. | 8 | $176 |
| Boehringer Ingelheim | 10 | $171 |
| Johnson & Johnson | 9 | $159 |
| Almatica Pharma LLC | 5 | $95 |
| Bayer | 6 | $93 |
| Idorsia Pharmaceuticals US Inc | 5 | $92 |
| Phathom Pharmaceuticals, Inc. | 3 | $75 |
| Exact Sciences | 4 | $74 |
| Merck | 4 | $74 |
| Daiichi Sankyo Inc. | 3 | $56 |
| Sanofi-aventis U.S. LLC | 2 | $47 |
| Lundbeck LLC | 2 | $37 |
| Photonicare Inc | 1 | $25 |
| Mylan Specialty L.p. | 1 | $24 |
| Agios Pharmaceuticals, Inc. | 1 | $24 |
| Alk-abello, Inc | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| 180 Medical, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,409 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 79 | $73,868 |
| OzempicSemaglutide | 29 | $48,767 |
| XareltoRivaroxaban | 28 | $39,288 |
| JardianceEmpagliflozin | 36 | $38,907 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $28,008 |
| JanuviaSitagliptin Phosphate | 27 | $20,527 |
| FarxigaDapagliflozin Propanediol | 15 | $18,152 |
| Bydureon BciseExenatide Microspheres | 14 | $14,888 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $14,133 |
| MyrbetriqMirabegron | 14 | $9,739 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 155 | $4,335 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $3,724 |
| Atorvastatin Calcium | 319 | $3,461 |
| Omeprazole | 138 | $3,072 |
| PaxlovidNirmatrelvir/Ritonavir | 23 | $2,859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $502 | $48,76729 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $311 | $42,14155 claims |
| Johnson & JohnsonXarelto | $159 | $39,28828 claims |
| Boehringer IngelheimJardiance | $171 | $38,90736 claims |
| MerckJanuvia | $74 | $20,52727 claims |
| AstraZenecaFarxiga | $199 | $18,15215 claims |
| AbbVieSynthroid | $487 | $2,57128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Palm Coast
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.